fbpx
QQQ
+ 1.81
292.66
+ 0.61%
DIA
-1.81
302.21
-0.6%
SPY
-0.65
363.79
-0.18%
TLT
-0.49
159.66
-0.31%
GLD
-0.08
169.67
-0.05%

The SAFE Act Could Be 2020's Biggest Cannabis Catalyst

December 16, 2019 11:32 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Cannabis investors are hoping Canada’s Cannabis 2.0 will help improve sales growth and profitability in 2020 after a disappointing 2019.

Yet the U.S. SAFE Act may be the single biggest catalyst for cannabis stocks in the coming year, Cantor Fitzgerald analyst Pablo Zuanic said in a Monday note. 

Cannabis 2.0 products such as edibles, vapes and beverages hit the shelves in Canada this week. While there’s no question the performance of these products is big fundamental news for cannabis stocks, Zuanic said all eyes are on the SAFE Act heading into 2020.

About The SAFE Act

The SAFE Act stops short of legalizing cannabis on a federal level, but it would lift the limitations on investments by banks and investment funds in cannabis companies in states where they are legal.

Following the MJBiz conference last week, Zuanic said Monday that the SAFE Act could have a chance of passing in the Republican-controlled Senate. The legislation has already made it through the Democrat-controlled House.

Cannabis could become a central part of the 2020 election season depending on how things shake out in the primaries, the analyst said. 

"While we do not think the views of the current President on the question of federal cannabis legalization will be known until the Democrats choose their candidate (i.e., if Joe Biden continues to think of cannabis as a ‘gateway drug,’ that could provide an opening for the incumbent President, in our view), we think there is a greater possibility SAFE could pass in the US than cannabis become federally legal."

For now, Zuanic is bullish on the following cannabis stocks:

  • Aurora Cannabis Inc (NYSE:ACB): Overweight rating, CA$5.85 ($4.46) price target.
  • Aphria Inc (NYSE:APHA): Overweight rating, CA$10.40 price target.
  • OrganiGram Holdings Inc (NASDAQ:OGI): Overweight rating, CA$13.30 price target.

Benzinga’s Take

Don’t expect the Senate to take action on the SAFE Act anytime soon. It would make strategic sense for Republicans to use passage or rejection of the SAFE Act as a strategic part of election season if the need arises, depending on the political climate.

Do you agree with this take? Email feedback@benzinga.com with your thoughts.

Related Links:

Hexo's Q1 Report Could Be Ugly, Says Cantor Fitzgerald

Is Cannabis The Liquor Industry's Worst Nightmare?


Related Articles

Cannabis Movers & Shakers: Cannabis Growth Opportunity, Bhang, CanaFarma Hemp, Amfil Technologies

Here is a summary of the latest company shakeups within the cannabis industry. 3 Execs Exit Cannabis Growth Opportunity Investment company Cannabis Growth Opportunity Corporation (CSE: CGOC) has parted ways with several executives. read more

Her Highness Enters Nevada Market Via Body And Mind Partnership

Women-centric cannabis brand Her Highness is expanding into Nevada through a production licensing partnership with MSO Body and Mind Inc. (CSE: BAMM). Her Highness products are now available across Nevada dispensaries. read more

Tyson Hypes Smart Cups Ahead Of Jones Fight, Tells Benzinga It's 'Disrupting Beverage Industry'

Boxing legend Mike Tyson has inked a long-term, multi-million-dollar deal with Smart Cups, a company that makes 3D-printed, single serve drinks. In an exclusive interview with Benzinga, Tyson revealed he’s been using Smart Cups to train for his exhibition against Roy Jones Jr., scheduled to take place this Thanksgiving weekend on Nov. 28. read more

Social Equity Measures Are Crucial On Day One Of Legalization, Cannabis Advocates Say

While the cannabis industry celebrated five states passing reform initiatives on Election Day, advocates noticed that the bills lacked key parameters to address social equity. read more

'CBD Is Not A Narcotic': European Court Rules Against Restrictions On CBD Commerce

The European Court of Justice ruled on a crucial case last week that could have large consequences over the commercialization of CBD across Europe. read more